Published in Cancer Immunol Immunother on November 16, 2010
'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation (2015) 0.98
Anti-yo associated paraneoplastic cerebellar degeneration in a man with large cell cancer of the lung. Case Rep Neurol Med (2013) 0.91
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration. PLoS One (2013) 0.90
Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4. J Neuroimmunol (2016) 0.85
Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol (2014) 0.84
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol (2014) 0.80
Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration. Neuro Oncol (2012) 0.76
Cell-mediated immune responses in paraneoplastic neurological syndromes. Clin Dev Immunol (2013) 0.76
Paraneoplastic syndromes involving the nervous system. N Engl J Med (2003) 5.46
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev (1999) 1.32
Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res (2000) 1.11
Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem (2007) 1.09
Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother (2009) 1.06
A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci (1997) 0.99
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol (2006) 0.98
Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol (2008) 0.98
Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand (2009) 0.96
The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells. PLoS One (2010) 0.94
PKN interacts with a paraneoplastic cerebellar degeneration-associated antigen, which is a potential transcription factor. Exp Cell Res (1998) 0.90
Differential expression of the neuroendocrine genes Hel-N1 and HuD in small-cell lung carcinoma: evidence for down-regulation of HuD in the variant phenotype. Int J Cancer (1997) 0.89
Effect of a paraneoplastic cerebellar degeneration-associated neural protein on B-myb promoter activity. Neurobiol Dis (2004) 0.84
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene (2009) 0.84
Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer (2010) 0.84
Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol (2005) 0.83
Interaction of a paraneoplastic cerebellar degeneration-associated neuronal protein with the nuclear helix-loop-helix leucine zipper protein MRG X. Mol Cell Neurosci (2002) 0.82
HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol (2010) 0.82
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo). Cancer Immunol Immunother (2010) 0.80
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol (2003) 2.85
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol (2004) 1.39
[Baby with respiratory problems and cardiac arrest]. Tidsskr Nor Laegeforen (2012) 1.39
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer (2009) 1.35
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res (2013) 1.21
Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res (2006) 1.19
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res (2011) 1.19
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer (2011) 1.19
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer (2013) 1.17
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol (2008) 1.15
Biologic markers in endometrial cancer treatment. APMIS (2009) 1.12
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem (2007) 1.09
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol (2012) 1.06
Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother (2009) 1.06
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res (2002) 1.03
Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res (2011) 1.03
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One (2013) 1.02
Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.02
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res (2013) 0.97
[Limbic encephalitis--a diagnostic challenge]. Tidsskr Nor Laegeforen (2007) 0.95
Immunoglobulin G fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis. J Rheumatol (2002) 0.94
Progressive striatal necrosis associated with anti-NMDA receptor antibodies. BMC Neurol (2013) 0.93
Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer (2012) 0.92
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol (2006) 0.92
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother (2006) 0.92
A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue. PLoS One (2011) 0.92
A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. J Proteome Res (2010) 0.91
MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol (2003) 0.91
Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol (2010) 0.91
A unified framework for automated 3-d segmentation of surface-stained living cells and a comprehensive segmentation evaluation. IEEE Trans Med Imaging (2009) 0.90
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration. PLoS One (2013) 0.90
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol (2009) 0.90
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res (2013) 0.89
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Hum Genet (2014) 0.89
Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res (2002) 0.89
Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) (2008) 0.89
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer (2013) 0.89
Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists. Eur Radiol (2012) 0.88
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol (2008) 0.88
Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. Int J Cancer (2006) 0.88
Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology (2009) 0.88
Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol (2011) 0.87
Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. Gynecol Oncol (2013) 0.87
Trans-10, cis-12-conjugated linoleic acid reduces the hepatic triacylglycerol content and the leptin mRNA level in adipose tissue in obese Zucker fa/fa rats. Br J Nutr (2009) 0.87
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer (2014) 0.87
The Norwegian Stroke in the Young Study (NOR-SYS): rationale and design. BMC Neurol (2013) 0.86
Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis (2005) 0.86
Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol (2011) 0.86
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Anal Biochem (2007) 0.86
Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur Radiol (2013) 0.86
Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecol Oncol (2012) 0.86
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. J Neuroimmunol (2005) 0.85
Neurological manifestations related to level of voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry (2013) 0.85
TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity (2002) 0.84
Follow-up routines in gynecological cancer - time for a change? Acta Obstet Gynecol Scand (2011) 0.84
Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology (2005) 0.84
Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum. J Neuroimmunol (2004) 0.84
GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer (2013) 0.84
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol (2012) 0.84
Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol (2009) 0.84
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk. PLoS One (2012) 0.84
Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas. Gynecol Oncol (2012) 0.84
Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol (2005) 0.83
Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer (2009) 0.83
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget (2014) 0.82
Arterial events after ischemic stroke at a young age: a cross-sectional long-term follow-up of patients and controls in western Norway. Cerebrovasc Dis (2007) 0.82
Pretreatment of mass spectral profiles: application to proteomic data. Anal Chem (2007) 0.82
Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother (2014) 0.82
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses (2012) 0.82
Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases/small cell lung cancer. J Neuroimmunol (2012) 0.81
Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis. J Neurol (2009) 0.81
Dietary soya protein concentrate enriched with isoflavones reduced fatty liver, increased hepatic fatty acid oxidation and decreased the hepatic mRNA level of VLDL receptor in obese Zucker rats. Br J Nutr (2006) 0.81
Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci (2002) 0.81
Immunoglobulin KM genes in Guillain-Barré syndrome. Neurogenetics (2003) 0.81
Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev (2012) 0.81
Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. Int J Gynecol Cancer (2015) 0.81